Shares of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) have been assigned a consensus recommendation of “Hold” from the nine ratings firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $5.00.
Several equities research analysts have recently commented on the stock. ValuEngine downgraded shares of AcelRx Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, October 12th. Jefferies Group downgraded shares of AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, October 13th. Royal Bank Of Canada decreased their target price on shares of AcelRx Pharmaceuticals from $6.00 to $5.00 and set an “outperform” rating for the company in a research report on Friday, October 13th. Roth Capital set a $8.00 target price on shares of AcelRx Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, October 12th. Finally, HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of AcelRx Pharmaceuticals in a research report on Friday, October 27th.
AcelRx Pharmaceuticals (NASDAQ:ACRX) traded down $0.10 during trading hours on Thursday, hitting $2.15. 238,035 shares of the stock traded hands, compared to its average volume of 980,700. The company has a quick ratio of 4.71, a current ratio of 4.78 and a debt-to-equity ratio of -0.43. AcelRx Pharmaceuticals has a one year low of $1.55 and a one year high of $5.75.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Perennial Advisors LLC purchased a new position in AcelRx Pharmaceuticals in the third quarter valued at about $138,000. Virtu KCG Holdings LLC boosted its stake in AcelRx Pharmaceuticals by 600.9% in the second quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock valued at $255,000 after acquiring an additional 101,742 shares during the last quarter. LMR Partners LLP purchased a new position in AcelRx Pharmaceuticals in the second quarter valued at about $319,000. Geller Family Office Services LLC purchased a new position in AcelRx Pharmaceuticals in the third quarter valued at about $460,000. Finally, Goldman Sachs Group Inc. purchased a new position in AcelRx Pharmaceuticals in the second quarter valued at about $530,000. Hedge funds and other institutional investors own 13.94% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.americanbankingnews.com/2017/12/07/acelrx-pharmaceuticals-inc-acrx-receives-consensus-recommendation-of-hold-from-analysts.html.
AcelRx Pharmaceuticals Company Profile
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.